Psybio Therapeutics Corp Stock Probability of Future Pink Sheet Price Finishing Under -0.002971
| PSYBF Stock | USD 0.0001 0.00 0.00% |
PsyBio |
PsyBio Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of PsyBio Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for PsyBio Therapeutics Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders |
PsyBio Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of PsyBio Pink Sheet often depends not only on the future outlook of the current and potential PsyBio Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. PsyBio Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 113 M | |
| Shares Float | 65 M |
PsyBio Therapeutics Technical Analysis
PsyBio Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. PsyBio Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of PsyBio Therapeutics Corp. In general, you should focus on analyzing PsyBio Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
PsyBio Therapeutics Predictive Forecast Models
PsyBio Therapeutics' time-series forecasting models is one of many PsyBio Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary PsyBio Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about PsyBio Therapeutics Corp
Checking the ongoing alerts about PsyBio Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for PsyBio Therapeutics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| PsyBio Therapeutics is way too risky over 90 days horizon | |
| PsyBio Therapeutics has some characteristics of a very speculative penny stock | |
| PsyBio Therapeutics appears to be risky and price may revert if volatility continues | |
| PsyBio Therapeutics Corp has accumulated 207.81 K in total debt with debt to equity ratio (D/E) of 7.03, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PsyBio Therapeutics Corp has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist PsyBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, PsyBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like PsyBio Therapeutics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for PsyBio to invest in growth at high rates of return. When we think about PsyBio Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (11.02 M) with loss before overhead, payroll, taxes, and interest of (1.56 M). | |
| PsyBio Therapeutics Corp has accumulated about 911.83 K in cash with (6.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 26.0% of PsyBio Therapeutics outstanding shares are owned by corporate insiders |
Other Information on Investing in PsyBio Pink Sheet
PsyBio Therapeutics financial ratios help investors to determine whether PsyBio Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PsyBio with respect to the benefits of owning PsyBio Therapeutics security.